ZBH - Zimmer Biomet Holdings Inc
(NaN%)
SNP 500
Sell
Moderate Growth but Declining
46%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 7.2%
Operating Income Growth is -14.59%
Net Income Growth is -21.98%
Earnings Per Share (EPS) Growth is -19.86%
Net Margin is 8.57%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.98
Debt Ratio is 0.45
Current Debt to Net Income Ratio is 0.83
Total Debt to Total Assets Ratio is 0.33
Cash Flow is MODERATE
Cash from Operations Growth is 13.19%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Zimmer Biomet Holdings Inc (ZBH) - www.zimmerbiomet.com
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Electromedical and Electrotherapeutic Apparatus Manufacturing
Sector - Manufacturing
CEO - Bryan Hanson
Employees - 18,000
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2026 and future.
Know the Stock © 2026 and future.